9
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T62783 | RIPK2-IN-1 | ||
RIPK2-IN-1 (compound 18f) is a potent inhibitor of RIPK2 (IC50: 51 nM) and also inhibits ALK2 (IC50: 5 nM). | |||
T5401 | GSK2983559 active metabolite | GSK2983559,RIPK2 inhibitor 1,RIPK2-IN-1 | RIP kinase |
GSK2983559 active metabolite (RIPK2-IN-1) is a potent, selective receptor-interacting protein-2 (RIP2) kinase inhibitor. | |||
T79352 | RIPK2/3-IN-1 | RIP kinase | |
RIPK2/3-IN-1 is a potent inhibitor of both RIPK2 and RIPK3 kinases, exhibiting IC50 values of 3 nM for RIPK2 and 117 nM for RIPK3. Additionally, in a 14-TriLAN-Gly/NOD1 THP-1 cell-based NF-κB reporter assay, RIPK2/3-IN-1... | |||
T63544 | RIPK3-IN-1 | ||
RIPK3-IN-1 is a type II RIPK3DFG-out site inhibitor (IC50: 9.1 nM) that inhibits RIPK1 (IC50: 5.5 μM) and RIPK2 (IC50>10 μM). RIPK3-IN-1 is a c-Met kinase inhibitor (IC50: 1.1 μM). | |||
T79600 | Zharp2-1 | RIP kinase | |
Zharp2-1, a RIPK2 inhibitor, inhibits the transcription of inflammatory cytokines induced by MDP-induced or Listeria monocytogenes infection and alleviates MDP-induced peritonitis symptoms in mice, which can be used for ... | |||
T74572 | RIPK2-IN-2 | ||
RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor that effectively blocks RIP2-dependent proinflammatory signaling and regulates RIP2 kinase activity in autoinflammatory diseases [1]. | |||
T78597 | RIPK2-IN-3 | RIP kinase | |
RIPK2-IN-3 (FCG806791773) is a receptor-interacting protein kinase 2 (RIPK2) inhibitor with an IC50 value of 6.39 μM against recombinant truncated RIPK2. It is applicable in the study of inflammation and cancer [1]. | |||
T19250 | CRIPGBM | TNF | |
cRIPGBM, a proapoptotic derivative of RIPGBM, selectively induces apoptosis in GBM cancer stem cells (CSCs) by targeting receptor-interacting protein kinase 2 (RIPK2), demonstrating an EC50 of 68 nM in GBM-1 cells [1]. | |||
T72658 | CRIPGBM chloride | ||
cRIPGBM chloride is an orally active, proapoptotic compound derived from glioblastoma multiforme (GBM) cancer stem cells (CSCs). It specifically targets receptor-interacting protein kinase 2 (RIPK2) to trigger caspase 1-... |